Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
about
Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer researchFormal consensus method to evaluate the conformity of prescription of a recently approved chemotherapy treatment in an observatory studyGuidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 studyThe Norwegian dietary guidelines and colorectal cancer survival (CRC-NORDIET) study: a food-based multicentre randomized controlled trial.Inconsistent selection and definition of local and regional endpoints in breast cancer research.Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.Defining clinically important perioperative blood loss and transfusion for the Standardised Endpoints for Perioperative Medicine (StEP) collaborative: a protocol for a scoping review.Bayesian survival analysis in clinical trials: What methods are used in practice?Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials.Immuno-Oncology: The Third Paradigm in Early Drug Development.Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial
P2860
Q26995439-3DF6FC48-C481-4623-9146-F2254F0C62F2Q28545286-0AABB4F9-E052-4B13-82C7-267807C04E8FQ35214578-007C3390-8DE2-43E8-B8C7-1B4DF1888A54Q35602143-E0CA3855-BC3F-499E-AA3B-DB1D4DE73E64Q36264150-C4DEB448-937A-4B98-A373-70806FBC0AF9Q38259456-C26BB1AB-0B98-4990-952E-CA9575EEC785Q38586999-233053F0-C2FD-464F-B33E-52CACD185502Q38699246-4F645943-7354-4CD4-8AC1-734C658A4A02Q38978314-98D2C9A3-B558-4BAB-A33F-193BF9DD0CC4Q39034554-9551C8EA-40F3-4D13-BACD-E63A0FDCF5DDQ39044147-78E86F2C-C225-455D-9502-FFD4D8F3A0A0Q48037262-3A1732AC-F2BA-458F-A328-B1564D20E0B4Q58707448-86BE76FA-528B-4BF1-8560-8067A1CB75F3
P2860
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Protocol of the Definition for ...... ons in cancer clinical trials.
@en
type
label
Protocol of the Definition for ...... ons in cancer clinical trials.
@en
prefLabel
Protocol of the Definition for ...... ons in cancer clinical trials.
@en
P2093
P50
P1476
Protocol of the Definition for ...... ions in cancer clinical trials
@en
P2093
Andrew Kramar
Anne Auperin
Catherine Fortpied
Christophe Le Tourneau
Franck Bonnetain
Laurence Collette
Marina Pulido
Monia Ouali
Murielle Mauer
Simone Mathoulin-Pélissier
P304
P356
10.1016/J.EJCA.2012.09.035
P577
2012-11-02T00:00:00Z